Mabpharm-B (02181) announced its financial results for the year ended December 31, 2025. The company recorded revenue of CNY646 million, representing a year-on-year increase of 150.2%. Profit attributable to owners of the company was CNY57.1 million, a significant improvement from a loss in the previous year. Basic earnings per share were CNY0.01. The turnaround to profitability was primarily attributed to an increase in gross profit and the recognition of deductible income tax for the coming year as a deferred tax expense.